Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Colorcon
Medtronic
McKesson
Boehringer Ingelheim

Last Updated: December 7, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for GS-9674


Email this page to a colleague

« Back to Dashboard

What is the drug development status for GS-9674?

GS-9674 is an investigational drug.

There have been 11 clinical trials for GS-9674. The most recent clinical trial was a Phase 2 trial, which was initiated on March 27th 2019.

The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Cholangitis. The leading clinical trial sponsors are Gilead Sciences, Novo Nordisk A/S, and [disabled in preview].

There are eight US patents protecting this investigational drug and one hundred and twenty international patents.

Recent Clinical Trials for GS-9674
TitleSponsorPhase
Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Participants With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)Novo Nordisk A/SPhase 2
Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Participants With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)Gilead SciencesPhase 2
Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated CirrhosisGilead SciencesPhase 1

See all GS-9674 clinical trials

Clinical Trial Summary for GS-9674

Top disease conditions for GS-9674
Top clinical trial sponsors for GS-9674

See all GS-9674 clinical trials

US Patents for GS-9674

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GS-9674 ⤷  Try it Free FXR agonists and methods for making and using Salk Institute for Biological Studies (La Jolla, CA) ⤷  Try it Free
GS-9674 ⤷  Try it Free FXR (NR1H4) binding and activity modulating compounds GILEAD SCIENCES, INC. (Foster City, CA) ⤷  Try it Free
GS-9674 ⤷  Try it Free FXR (NR1H4) modulating compounds Gilead Sciences, Inc. (Foster City, CA) ⤷  Try it Free
GS-9674 ⤷  Try it Free Acyclic antivirals Janssen BioPharma, Inc. (South San Francisco, CA) ⤷  Try it Free
GS-9674 ⤷  Try it Free FXR (NR1H4) binding and activity modulating compounds Gilead Sciences, Inc. (Foster City, CA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GS-9674

Drugname Country Document Number Estimated Expiration Related US Patent
GS-9674 Australia AU2015229072 2034-03-13 ⤷  Try it Free
GS-9674 Canada CA2942403 2034-03-13 ⤷  Try it Free
GS-9674 European Patent Office EP3116878 2034-03-13 ⤷  Try it Free
GS-9674 Japan JP2017510572 2034-03-13 ⤷  Try it Free
GS-9674 South Korea KR20160132111 2034-03-13 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Colorcon
Medtronic
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.